Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799877 | 0.93 | CTSB (0.44) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL2795960 | 0.92 | CTSB (0.44) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL9958019 | 0.91 | CTSB (0.45) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL2800132 | 0.90 | CTSB (0.43) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL7890621 | 0.87 | CYP3A4 (0.43) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL2797181 | 0.87 | CYP3A4 (0.43) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL13975791 | 0.87 | CYP3A4 (0.45) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL2799662 | 0.87 | CYP3A4 (0.43) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL2131121 | 0.87 | CYP3A4 (0.45) | CTSBCYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL2133366 | 0.87 | CYP3A4 (0.45) | CTSBCYP3A4ADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232246-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | claimed |
| US-8232246-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232246-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168384-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CTSB 275/4885CYP3A4 2043/4885ADRB3 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.